a Pulmonary Research Institute at LungenClinic Großhandorf , Großhansdorf , Germany.
b Sofotec GmbH, a member of the AstraZeneca Group , Bad Homburg , Germany.
COPD. 2019 Apr;16(2):196-205. doi: 10.1080/15412555.2019.1630807. Epub 2019 Jul 2.
This article reviews the latest data pertaining to the Genuair/Pressair device, a breath-actuated, multi-dose dry-powder inhaler with a two-step inhalation process, which is marketed for the delivery of aclidinium alone or in combination with formoterol for long-term maintenance bronchodilation treatment in chronic obstructive pulmonary disease. It contains multiple feedback mechanisms to guide effective use, and safety features to avoid double-dosing or attempted use when empty. In addition to describing the design of Genuair, the article will provide an update on inhaler operability and performance, focusing on recent patient preference and satisfaction studies. The evidence suggests that patients find Genuair easy to use, with patients requiring less training and making fewer inhalation errors than with other inhalers, and that patient satisfaction with the device is high.
这篇文章回顾了与 Genuair/Pressair 装置相关的最新数据，该装置是一种由呼吸触发的、多剂量干粉吸入器，采用两步吸入过程，市场上用于输送单独的阿地溴铵或与福莫特罗联合使用，用于慢性阻塞性肺疾病的长期维持性支气管扩张治疗。它包含多种反馈机制，以指导有效使用，并具有安全功能，可避免在空药盒时发生重复剂量或尝试使用。除了描述 Genuair 的设计外，本文还将提供关于吸入器操作性和性能的最新信息，重点介绍最近的患者偏好和满意度研究。证据表明，患者发现 Genuair 易于使用，与其他吸入器相比，患者需要的培训更少，吸入错误更少，而且患者对该设备的满意度很高。
